>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • NEGG +6.6%, AMYT +1.2%

Select metals/mining stocks trading higher:

  • MT +1.5%, CLF +1%, X +1%, RIO +0.9%, BHP +0.9%, . 

Select oil/gas related names showing strength:

  • RDS.A +1.5%, OIH +1.4%, SLB +1.1%, BP +1.1%, HAL +1.1%, XLE +0.8%, XOM +0.8%, USO +0.7%, . 

Other news:

  • HEPA +17.5% (schedules conference call to review data from Phase 2a ‘AMBITION' clinical trial of CRV431 in NASH )
  • ADAP +14.2% (announces updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the upcoming European Society for Medical Oncology annual meeting)
  • MIRM +4.7% (submits European Marketing Authorization Application for maralixibat in alagille syndrome supported by new positive results from natural history study comparison)
  • DDI +3.8% (Shareholder B. Riley Financial (RILY) announced intention to purchase additional shares)
  • SIGA +3.8% (receives BARDA exercise of procurement option valued at $112.5 mln for oral TPOXX)
  • GSM +3.7% (files for 91,708,179 ordinary stock offering by selling shareholder)
  • HCM +3% (receives breakthrough therapy designation in China for Amdizalisib)
  • CYTK +2.6% (reports results from REDWOOD-HCM and GALACTIC-HF presented in late breaking clinical trial session at the HFSA Annual Scientific Meeting)
  • CPG +2.4% (increases dividend and provides preliminary 2022 budget)
  • LMPX +2.3% (to purchase an 85% interest in the Alan Jay Automotive Network; expects to be accretive to adj. EBITDA in 2022)
  • SPRT +1.6% (follow-up to special meeting vote on merger)
  • RDHL +1.5% (accelerates ongoing U.S. Phase 2/3 COVID-19 study of once-daily oral RHB-107 in Non-hospitalized patients with South African approval)
  • REPH +1.4% (files for 9,302,718 share common stock offering by selling shareholders)
  • ASPN +1% (files for 3,462,124 share common stock offering by selling shareholder) . 

Analyst comments:

  • DELL +2.1% (upgraded to Conviction Buy from Buy at Goldman )
  • CG +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)